Table 10 Whole mouth percent bleeding sites (based on EBI) at Weeks 4 and 12

Baseline

n

53

51

52

50

52

Mean

24.9

24.8

28.8

26.8

25.4

(SD)

11.52

11.54

12.15

10.43

11.08

Week 4

N

53

51

52

50

52

LSmean (SE)

19.4 (0.73)

6.5 (0.74)

6.6 (0.74)

14.6 (0.75)

5.9 (0.73)

Treatment groups versus B

p-value

< 0.001

< 0.001

< 0.001

< 0.001

Difference (SE)

-12.9 (1.04)

-12.8 (1.04)

-4.8 (1.04)

-13.5 (1.03)

95% CI

[-15.0, -10.9]

[-14.9, -10.8]

[-6.9, -2.8]

[-15.6, -11.5]

% reduction

66.6

66.1

24.8

69.7

Brush/Rinse groups versus Brush/Floss Superiority

p-value

< 0.001

< 0.001

Difference (SE)

-8.1 (1.05)

-8.0 (1.05)

95% CI

[-10.2, -6.0]

[-10.1, -5.9]

% reduction

55.5

54.9

BFZ versus BF Superiority

p-value

< 0.001

Difference (SE)

-8.7 (1.05)

95% CI

[-10.8, -6.7]

% reduction

59.7

BFZ versus BZ

p-value

0.498

Difference (SE)

-0.7 (1.04)

95% CI

[-2.8, 1.3]

% reduction

10.7

Week 12

N

52

50

52

50

50

LSmean (SE)

21.2 (0.90)

7.4 (0.92)

7.1 (0.90)

16.6 (0.92)

6.1 (0.91)

Treatment groups versus B

p-value

< 0.001

< 0.001

< 0.001

< 0.001

Difference (SE)

-13.8 (1.28)

-14.1 (1.28)

-4.7 (1.28)

-15.2 (1.28)

95% CI

[-16.4, -11.3]

[-16.6, -11.6]

[-7.2, -2.1]

[-17.7, -12.6]

% reduction

65.2

66.5

22.0

71.4

Brush/Rinse groups versus BF Superiority

p-value

< 0.001

< 0.001

Difference (SE)

-9.2 (1.30)

-9.5 (1.29)

95% CI

[-11.7, -6.6]

[-12.0, -6.9]

% reduction

55.4

57.1

BFZ versus BF Superiority

p-value

< 0.001

Difference (SE)

-10.5 (1.30)

95% CI

[-13.0, -7.9]

% reduction

63.4

BFZ versus BZ Superiority

p-value

0.419

Difference (SE)

-1.0 (1.29)

95% CI

[-3.6, 1.5]

% reduction

14.7